Preclinical support for tumor protein D52 as a cancer vaccine antigen

References

• American Cancer Society. Cancer facts & figures 2023. Atlanta: American Cancer Society; 2023.
   Google Scholar
• Mellman I, Coukos G, Dranoff G. Cancer immunotherapy come of age. Nature. 2011;480(7378):480–11. doi:10.1038/nature10673.
   PubMed Web of Science ®Google Scholar
• Couzin-Frankel J. Cancer immunotherapy. Sci. 2013;342(6165):1432–3. doi:10.1126/science.342.6165.1432.
   PubMed Web of Science ®Google Scholar
• Weber JS, Kahler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol. 2012;30(21):2691–7. doi:10.1200/JCO.2012.41.6750.
   PubMed Web of Science ®Google Scholar
• Lewis JD, Reilly BD, Bright RK. Tumor-associated antigens: from discovery to immunity. Int Rev Immunol. 2003;22(2):81–112. doi:10.1080/08830180305221.
   PubMed Web of Science ®Google Scholar
• Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Sci. 2015;348(6230):69–74. doi:10.1126/science.aaa4971.
   PubMed Web of Science ®Google Scholar
• Schumacher TN, Scheper W, Kvistborg P. Cancer neoantigens. Annu Rev Immunol. 2019;37(1):173–200. doi:10.1146/annurev-immunol-042617-053402.
   PubMedGoogle Scholar
• Bright RK, Bright JD, Byrne JA. Overexpressed oncogenic tumor-self antigens: new vaccine targets. Hum Vaccin Immunother. 2014;10(11):3297–305. doi:10.4161/hv.29475.
   PubMed Web of Science ®Google Scholar
• Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, Mellman I, Prindiville SA, Viner JL, Weiner LM, et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res. 2009;15(17):5323–37. doi:10.1158/1078-0432.CCR-09-0737.
   PubMed Web of Science ®Google Scholar
• Augello MA, Den RB, Knudsen KE. AR function in promoting metastatic prostate cancer. Cancer Metastasis Rev. 2014;33(2–3):399–411. doi:10.1007/s10555-013-9471-3.
   PubMed Web of Science ®Google Scholar
• McNamara KM, Yoda T, Nurani AM, Shibahara Y, Miki Y, Wang L, Nakamura Y, Suzuki K, Yang Y, Abe E, et al. Androgenic pathways in the progression of triple-negative breast carcinoma: a comparison between aggressive and non-aggressive subtypes. Breast Cancer Res Treat. 2014;145(2):281–93. doi:10.1007/s10549-014-2942-6.
   PubMed Web of Science ®Google Scholar
• Olson BM, Johnson LE, McNeel DG. The androgen receptor: a biologically relevant vaccine target for the treatment of prostate cancer. Cancer Immunol Immunother. 2013;62(3):585–96. doi:10.1007/s00262-012-1363-9.
   PubMed Web of Science ®Google Scholar
• Wiedman U, Davis AB, Zielinski CC. Vaccination for the prevention and treatment of breast cancer with special focus on Her-2/neu peptide vaccines. Breast Cancer Res Treat. 2013;138(1):1–12. doi:10.1007/s10549-013-2410-8.
   PubMed Web of Science ®Google Scholar
• Baxevanis CN, Voutsas IF, Gritzapis AD, Perez SA, Papamichail M. Her-2/neu as a target for cancer vaccines. Immuotherapy. 2010;2(2):213–26. doi:10.2217/imt.09.89.
   PubMed Web of Science ®Google Scholar
• Tobias J, Garner-Spitzer E, Drinić M, Wiedermann U. Vaccination against Her-2/neu, with focus on peptide-based vaccines. ESMO Open. 2022;7(1):100361. doi:10.1016/j.esmoop.2021.100361.
   PubMed Web of Science ®Google Scholar
• Leffers N, Vermeij R, Hoogeboom BN, Schulze UR, Wolf R, Hamming IE, van der Zee AG, Melief KJ, van der Burg SH, Daemen T, et al. Long-term clinical and immunological effects of p53-SLP® vaccine in patients with ovarian cancer. Int J Cancer. 2012;130(1):10–12. doi:10.1002/ijc.25980.
   PubMed Web of Science ®Google Scholar
• Rahma OE, Ashtar E, Czystowska M, Szajnik ME, Wieckowski E, Bernstein S, Herrin VE, Shams MA, Steinberg SM, Merino M, et al. A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients. Cancer Immunol Immunother. 2012;61(3):373–84. doi:10.1007/s00262-011-1100-9.
   PubMed Web of Science ®Google Scholar
• Zeestraten EC, Speetjens FM, Welters MJ, Saadatmand S, Stynenbosch LF, Jongen R, Kapiteijn E, Gelderblom H, Nijman HW, Valentijn AR, et al. Addition of interferon-α to the p53-SLP® vaccine results in increased production of interferon-γ in vaccinated colorectal cancerpatients: a phase I/II clinical trial. Int J Cancer. 2013;132(7):1581–91. doi:10.1002/ijc.27819.
   PubMed Web of Science ®Google Scholar
• Hall RD, Gray JE, Chiappori AA. Beyond the standard of care: a review of novel immunotherapy trials for the treatment of lung cancer. Cancer Control. 2013;20(1):22–31. doi:10.1177/107327481302000105.
   PubMed Web of Science ®Google Scholar
• Zhou S, Fan C, Zeng Z, Young KH, Li Y. Clinical and immunological effects of p53-targeting vaccines. Front Cell Dev Biol. 2021;9:762796. doi:10.3389/fcell.2021.762796.
   PubMed Web of Science ®Google Scholar
• Chiappori AA, Williams CC, Gray JE, Tanvetyanon T, Haura EB, Creelan BC, Thapa R, Chen DT, Simon GR, Bepler G, et al. Randomized-controlled phase II trial of salvage chemotherapy after immunization with a TP53-transfected dendritic cell-based vaccine (Ad.P53-DC) in patients with recurrent small cell lung cancer. Cancer Immunol Immunother. 2019;68(3):517–27. doi:10.1007/s00262-018-2287-9.
   PubMed Web of Science ®Google Scholar
• Carlsen L, Zhang S, Tian X, De La Cruz A, George A, Arnoff TE, El-Deiry WS. The role of p53 in anti-tumor immunity and response to immunotherapy. Front Mol Biosci. 2023;10:1–13. doi:10.3389/fmolb.2023.1148389.
   Web of Science ®Google Scholar
• Park JE, Alexander IS, Zhou R. Roles of EphA2 in development and disease. Genes. 2013;4(3):334–57. doi:10.3390/genes4030334.
   PubMed Web of Science ®Google Scholar
• Yeung JT, Hamilton RL, Okada H, Jakacki RI, Pollack IF. Increased expression of tumor-associated antigens in pediatric and adult ependymomas: implication for vaccine therapy. J Neurooncol. 2013;111(2):103–11. doi:10.1007/s11060-012-0998-x.
   PubMed Web of Science ®Google Scholar
• Okada H, Kalinski P, Ueda R, Hoji A, Kohanbash G, Donegan TE, Mintz AH, Engh JA, Bartlett DL, Brown CK, et al. Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J Clin Oncol. 2011;29(3):330–6. doi:10.1200/JCO.2010.30.7744.
   PubMed Web of Science ®Google Scholar
• Ladomersky E, Genet M, Zhai L, Gritsina G, Lauing KL, Lulla RR, Fangusaro J, Lenzen A, Kumthekar P, Raizer JJ, et al. Improving vaccine efficacy against malignant glioma. Oncoimmunology. 2016;5(8):e1196311. doi:10.1080/2162402X.2016.1196311.
   PubMed Web of Science ®Google Scholar
• Beatty GL, Vonderheide RH. Telomerase as a universal tumor antigen for cancer vaccines. Expert Rev Vaccines. 2008;7(7):881–7. doi:10.1586/14760584.7.7.881.
   PubMed Web of Science ®Google Scholar
• Carpenter EL, Vonderheide RH. Telomerase-based immunotherapy of cancer. Expert Opin Biol Ther. 2006;6(10):1031–9. doi:10.1517/14712598.6.10.1031.
   PubMed Web of Science ®Google Scholar
• Vonderheide RH, Domchek SM, Schultze JL, George DJ, Hoar KM, Chen DY, Stephans KF, Masutomi K, Loda M, Xia Z, et al. Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes. Clin Cancer Res. 2004;10(3):828–39. doi:10.1158/1078-0432.CCR-0620-3.
   PubMed Web of Science ®Google Scholar
• Brunsvig PF, Kyte JA, Kersten C, Sundstrøm S, Møller M, Nyakas M, Hansen GL, Gaudernack G, Aamdal S. Telomerase peptide vaccination in NSCLC: a phase II trial in stage III patients vaccinated after chemoradiotherapy and an 8-year update on a phase I/II trial. Clin Ca Res. 2011;17(21):6847–57. doi:10.1158/1078-0432.CCR-11-1385.
   PubMed Web of Science ®Google Scholar
• Vetsika EK, Konsolakis G, Aggouraki D, Kotsakis A, Papadimitraki E, Christou S, Menez-Jamet J, Kosmatopoulos K, Georgoulias V, Mavroudis D. Immunological responses in cancer patients after vaccination with the therapeutic telomerase-specific vaccine Vx-001. Cancer Immunol Immunother. 2012;61(2):157–68. doi:10.1007/s00262-011-1093-4.
   PubMed Web of Science ®Google Scholar
• Ellingsen EB, Mangsbo SM, Hovig E, Gaudernack G. Telomerase as a target for therapeutic cancer vaccines and considerations for optimizing their clinical potential. Front Immunol. 2021;12:682492. doi:10.3389/fimmu.2021.682492.
   PubMed Web of Science ®Google Scholar
• Stauber RH, Mann W, Knauer SK. Nuclear and cytoplasmic survivin: molecular mechanism, prognostic, and therapeutic potential. Cancer Res. 2007;67(13):5999–6002. doi:10.1158/0008-5472.CAN-07-0494.
   PubMed Web of Science ®Google Scholar
• Andersen MH, Svane IM, Becker JC, Sraten PT. The universal character of the tumor-associated antigen survivin. Clinical Cancer Research. 2007;13(20):5991–4. doi:10.1158/1078-0432.CCR-07-0686.
   PubMed Web of Science ®Google Scholar
• Kameshima H, Tsuruma T, Kutomi G, Shima H, Iwayama Y, Kimura Y, Imamura M, Torigoe T, Takahashi A, Hirohashi Y, et al. Immunotherapeutic benefit of α-interferon (IFNα) in survivin2B-derived peptide vaccination for advanced pancreatic cancer patients. Cancer Sci. 2013;104(1):124–9. doi:10.1111/cas.12046.
   PubMed Web of Science ®Google Scholar
• Filipazzi P1, Pilla L, Mariani L, Patuzzo R, Castelli C, Camisaschi C, Maurichi A, Cova A, Rigamonti G, Giardino F, et al. Limited induction of tumor cross-reactive T cells without a measurable clinical benefit in early melanoma patients vaccinated with human leukocyte antigen class I–modified peptides. Clinical Cancer Research. 2012;18(23):6485–96. doi:10.1158/1078-0432.CCR-12-1516.
   PubMed Web of Science ®Google Scholar
• Becker JC1, Andersen MH, Hofmeister-Müller V, Wobser M, Frey L, Sandig C, Walter S, Singh-Jasuja H, Kämpgen E, Opitz A, et al. Survivin-specific T-cell reactivity correlates with tumor response and patient survival: a phase-II peptide vaccination trial in metastatic melanoma. Cancer Immunol Immunother. 2012;61(11):2091–103. doi:10.1007/s00262-012-1266-9.
   PubMed Web of Science ®Google Scholar
• Lee J, Uy BR, Liau LM. Brain tumor vaccines. Neurosurg Clin N Am. 2021;32(2):225–34. doi:10.1016/j.nec.2021.01.003.
   PubMed Web of Science ®Google Scholar
• Byrne JA, Frost S, Chen Y, Bright RK. Tumor protein D52 (TPD52) and cancer—oncogene understudy or understudied oncogene? Tumor Biol. 2014;35(8):7369–82. doi:10.1007/s13277-014-2006-x.
   PubMedGoogle Scholar
• Balleine RL, Schoenberg Fejzo M, Sathasivam P, Basset P, Clarke CL, Byrne JA. The D52 (TPD52) gene is a candidate target gene for events resulting in increased 8q21 copy number in human breast carcinoma. Genes Chromosom Cancer. 2000;29(1):48–57. doi:10.1002/1098-2264(2000)9999:9999<:AID-GCC1005>3.0.CO;2-O.
   PubMed Web of Science ®Google Scholar
• Byrne JA, Tomasetto C, Garnier JM, Rouyer N, Mattei MG, Bellocq JP, Rio MC, Basset PA. A screening method to identify genes commonly overexpressed in carcinomas and the identification of a novel complementary DNA sequence. Cancer Res. 1995;55:2896–903.
   PubMed Web of Science ®Google Scholar
• Pollack JR, Sørlie T, Perou CM, Rees CA, Jeffrey SS, Lonning PE, Tibshirani R, Botstein D, Børresen-Dale AL, Brown PO. Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. Proc Natl Acad Sci USA. 2002;99(20):12963–8. doi:10.1073/pnas.162471999.
   PubMed Web of Science ®Google Scholar
• Wang R, Xu J, Saramaki O, Visakorpi T, Sutherland WM, Zhou J, Sen B, Lim SD, Mabjeesh N, Amin M, et al. PrLZ, a novel prostate-specific and androgen-responsive gene of the TPD52 family, amplified in chromosome 8q21.1 and overexpressed in human prostate cancer. Cancer Research. 2004;64(5):1589–94. doi:10.1158/0008-5472.CAN-03-3331.
   PubMed Web of Science ®Google Scholar
• Wang R, Xu J, Mabjeesh N, Zhu G, Zhou J, Amin M, He D, Marshall FF, Zhau HE, Chung LW. PrLZ is expressed in normal prostate development and in human prostate cancer progression. Clin Cancer Res. 2007;13(20):6040–8. doi:10.1158/1078-0432.CCR-07-0640.
   PubMed Web of Science ®Google Scholar
• Rubin MA, Varambally S, Beroukhim R, Tomlins SA, Rhodes DR, Paris PL, Hofer MD, Storz-Schweizer M, Kuefer R, Fletcher JA, et al. Overexpression, amplification, and androgen regulation of TPD52 in prostate cancer. Cancer Res. 2004;64(11):3814–22. doi:10.1158/0008-5472.CAN-03-3881.
   PubMed Web of Science ®Google Scholar
• Byrne JA, Balleine RL, Schoenberg Fejzo M, Mercieca J, Chiew YE, Livnat Y, St Heaps L, Peters GB, Byth K, Karlan BY, et al. Tumor protein D52 (TPD52) is overexpressed and a gene amplification target in ovarian cancer. Int J Cancer. 2005;117(6):1049–54. doi:10.1002/ijc.21250.
   PubMed Web of Science ®Google Scholar
• Largo C, Alvarez S, Saez B, Blesa D, Martin-Subero JI, González-García I, Brieva JA, Dopazo J, Siebert R, Calasanz MJ, et al. Identification of overexpressed genes in frequently gained/amplified chromosome regions in multiple myeloma. Haematologica. 2006;91:184–91.
   PubMed Web of Science ®Google Scholar
• Tiacci E, Orvietani PL, Bigerna B, Pucciarini A, Corthals GL, Pettirossi V, Martelli MP, Liso A, Benedetti R, Pacini R, et al. Tumor protein D52 (TPD52): a novel B-cell/plasma-cell molecule with unique expression pattern and Ca(2+)-dependent association with annexin VI. Blood. 2005;105:2812–20. doi:10.1182/blood-2004-07-2630.
   PubMed Web of Science ®Google Scholar
• Dave SS, Fu K, Wright GW, Lam LT, Kluin P, Boerma EJ, Greiner TC, Weisenburger DD, Rosenwald A, Ott G, et al. Molecular diagnosis of Burkitts lymphoma. N Engl J Med. 2006;354(23):2431–42. doi:10.1056/NEJMoa055759.
   PubMed Web of Science ®Google Scholar
• Hummel M, Bentink S, Berger H, Klapper W, Wessendorf S, Barth TF, Bernd HW, Cogliatti SB, Dierlamm J, Feller AC, et al. A biologic definition of Burkitt’s lymphoma from transcriptional and genomic profiling. N Engl J Med. 2006;354(23):2419–30. doi:10.1056/NEJMoa055351.
   PubMed Web of Science ®Google Scholar
• Loukopoulos P, Shibata T, Katoh H, Kokubu A, Sakamoto M, Yamazaki K, Kosuge T, Kanai Y, Hosoda F, Imoto I, et al. Genome-wide array-based comparative genomic hybridization analysis of pancreatic adenocarcinoma: identification of genetic indicators that predict patient outcome. Cancer Sci. 2007;98(3):392–400. doi:10.1111/j.1349-7006.2007.00395.x.
   PubMed Web of Science ®Google Scholar
• Skotheim RI, Autio R, Lind GE, Kraggerud SM, Andrews PW, Monni O, Kallioniemi O, Lothe RA. Novel genomic aberrations in testicular germ cell tumors by array-CGH, and associated gene expression changes. Cell Oncol. 2006;28(5–6):315–26. doi:10.1155/2006/219786.
   PubMed Web of Science ®Google Scholar
• Korkola JE, Heck S, Olshen AB, Reuter VE, Bosl GJ, Houldsworth J, Chaganti RS. In vivo differentiation and genomic evolution in adult male germ cell tumors. Genes Chromosomes Cancer. 2008;47(1):43–55. doi:10.1002/gcc.20504.
   PubMed Web of Science ®Google Scholar
• McIntyre A, Summersgill B, Lu YJ, Missiaglia E, Kitazawa S, Oosterhuis JW, Looijenga LH, Shipley J. Genomic copy number and expression patterns in testicular germ cell tumours. Br J Cancer. 2007;97(12):1707–12. doi:10.1038/sj.bjc.6604079.
   PubMed Web of Science ®Google Scholar
• Hoek KS. DNA microarray analyses of melanoma gene expression: a decade in the mines. Pigment Cell Res. 2007;20(6):466–84. doi:10.1111/j.1600-0749.2007.00412.x.
   PubMedGoogle Scholar
• Roesch A, Becker B, Bentink S, Spang R, Vogl A, Hagen I, Landthaler M, Vogt T. Ataxia telangiectasia-mutated gene is a possible biomarker for discrimination of infiltrative deep penetrating nevi and metastatic vertical growth phase melanoma. Cancer Epidemiology, Biomarkers & Prevention. 2007;11(11):2486–90. doi:10.1158/1055-9965.EPI-07-0224.
   Google Scholar
• Byrne JA, Chen Y, Martin La Rotta N, Peters GB. Challenges in identifying candidate amplification targets in human cancers: chromosome 8q21 as a case study. Genes Cancer. 2012;3:87–101. doi:10.1177/1947601912456287.
   PubMedGoogle Scholar
• Wilson KS, Roberts H, Leck R, Harris AL, Geradts J. Differential gene expression patterns in Her-2/neu-positive and -negative breast cancer cell lines and tissues. The American Journal Of Pathology. 2002;161(4):1171–85. doi:10.1016/S0002-9440(10)64394-5.
   PubMed Web of Science ®Google Scholar
• Landis MD, Seachrist DD, Abdul-Karim FW, Keri RA. Sustained trophism of the mammary gland is sufficient to accelerate and synchronize development of ErB2/Neu-induced tumors. Oncogene. 2006;25(23):3325–34. doi:10.1038/sj.onc.1209365.
   PubMed Web of Science ®Google Scholar
• Chen H, Pimienta G, Gu Y, Sun X, Hu J, Kim M-S, Chaerkady R, Gucek M, Cole RN, Sukumar S, et al. Proteomic characterization of Her2/neu-overexpressing breast cancer cell lines. Proteomics. 2010;10(21):3800–10. doi:10.1002/pmic.201000297.
   PubMed Web of Science ®Google Scholar
• Shehata M, Bieche I, Boutros R, Weidenhofer J, Fanayan S, Spalding L, Zeps N, Byth K, Bright RK, Lidereau R, et al. Non-redundant functions for tumor protein D52-like proteins support specific targeting of TPD52. Clin Cancer Res. 2008;14(16):5050–60. doi:10.1158/1078-0432.CCR-07-4994.
   PubMed Web of Science ®Google Scholar
• Roslan N, Bieche I, Bright RK, Lidereau R, Chen Y, Byrne JA. TPD52 represents a survival factor in ERBB2-amplified breast cancer cells. Mol Carcinog. 2014;53(10):807–19. doi:10.1002/mc.22038.
   PubMed Web of Science ®Google Scholar
• Shehata M, Weidenhofer J, Thamotharampillai K, Hardy JR, Byrne JA. Tumor protein D52 overexpression and gene amplification in cancers from a mosaic of microarrays. Crit Rev Oncol. 2008;14(1):33–5. doi:10.1615/CritRevOncog.v14.i1.30.
   Google Scholar
• Haaland CM, Heaphy CM, Butler KS, Fischer EG, Griffith JK, Bisoffi M. Differential gene expression in tumor adjacent histologically normal prostatic tissue indicates field cancerization. Int J Oncol. 2009;35:537–46. doi:10.3892/ijo_00000365.
   PubMed Web of Science ®Google Scholar
• Bright RK, Lewis JD. Long-term culture of normal and malignant human prostate epithelial cells. In: Pfragner R Frehsney R, editors. Culture of specialized cells, culture of human tumor cells. Hoboken, NJ: John Wiley & Sons, Inc; 2003. pp. 125–44.
   Google Scholar
• Bright RK, Vocke CD, Emmert-Buck MR, Duray PH, Solomon D, Fetsch P, Rhim JS, Linehan WM, Topalian SL. Generation and genetic characterization of immortal human prostate epithelial cell lines derived from primary cancer specimens. Cancer Res. 1997;57:995–1002.
   PubMed Web of Science ®Google Scholar
• Liu W, Xie CC, Thomas CY, Kim ST, Lindberg J, Egevad L, Wang Z, Zhang Z, Sun J, Sun J, et al. Genetic markers associated with early cancer-specific mortality following prostatectomy. Cancer. 2013;119(13):2405–12. doi:10.1002/cncr.27954.
   PubMed Web of Science ®Google Scholar
• Virgin JB, Hurley PM, Nahhas F, Bebchuk KG, Mohamed AN, Sakr WA, Bright RK, Cher ML. Isochromosome 8q formation is associated with 8p loss of heterozygosity in a prostate cancer cell line. Prostate. 1999;41(1):49–57. doi:10.1002/(SICI)1097-0045(19990915)41:1<49:AID-PROS7>3.0.CO;2-8.
   PubMed Web of Science ®Google Scholar
• Bismar TA, Demichelis F, Riva A, Kim R, Varambally S, He L, Kutok J, Aster JC, Tang J, Kuefer R, et al. Defining aggressive prostate cancer using a 12-gene model. Neoplasia. 2006;8(1):59–68. doi:10.1593/neo.05664.
   PubMed Web of Science ®Google Scholar
• Byrne JA, Mattei MG, Basset P. Definition of the D52 gene/protein family through cloning of D52 homologues in human (hD53) and mouse (mD52). Genomics. 1996;35(3):523–32. doi:10.1006/geno.1996.0393.
   PubMed Web of Science ®Google Scholar
• Lewis JD, Payton LA, Whitford JG, Byrne JA, Smith DI, Yang L, Bright RK. Induction of tumorigenesis and metastasis by the murine orthologue of tumor protein D52. Mol Cancer Res. 2007;5(2):133–44. doi:10.1158/1541-7786.MCR-06-0245.
   PubMed Web of Science ®Google Scholar
• Bright RK. Cancer vaccines: the next generation immunotherapy. Int J Vaccine Immun. 2015;2(1):1–2. doi:10.16966/2470-9948.105.
   Google Scholar
• Stritesky GL, Jameson SC, Hogquist KA. Selection of self-reactive T cells in the thymus. Annu Rev Immunol. 2012;30(1):95–114. doi:10.1146/annurev-immunol-020711-075035.
   PubMedGoogle Scholar
• Bright RK, Mamula MJ. Regulation of adaptive immune responses to self-antigens in cancer and autoimmunity. Curr Trends Immunol. 2014;15:47–57.
   Google Scholar
• Payton LA, Lewis JD, Byrne JA, Bright RK. Vaccination with the metastasis-related tumor associated antigen TPD52 and CpG/ODN induces protective tumor immunity. Cancer Immunol Immunother. 2008;57(6):799–811. doi:10.1007/s00262-007-0416-y.
   PubMed Web of Science ®Google Scholar
• Lewis JD, Sullivan LA, Byrne JA, DeRiese W, Bright RK. Memory and cellular immunity induced by a DNA vaccine encoding self antigen TPD52 administered with soluble GM-CSF. Cancer Immunol Immunother. 2009;58(8):1337–49. doi:10.1007/s00262-009-0659-x.
   PubMed Web of Science ®Google Scholar
• Bright JD, Schultz HN, Byrne JA, Bright RK. Injection site and regulatory T cells influence durable vaccine-induced tumor immunity to an over-expressed self tumor associated antigen. OncoImmunol. 2013;2(7):e25049-1–11. doi:10.4161/onci.25049.
   Web of Science ®Google Scholar
• Bright JD, Aldrich JF, Byrne JA, Bright RK. Vaccination with the prostate cancer over-expressed tumor-self protein TPD52 elicits protective tumor immunity and a potentially unique subset of CD8+ T cells. Au J Clin Immunol. 2014;1:1–13. http://www.austinpublishinggroup.com/clinical-immunology/fulltext/ajci-v1-id1007.php.
   Google Scholar
• Gingrich JR, Barrios RJ, Morton RA, Boyce BF, DeMayo FJ, Finegold MJ, Angelopoulou R, Rosen JM, Greenberg NM. Metastatic prostate cancer in a transgenic mouse. Cancer Res. 1996;56:4096–102.
   PubMed Web of Science ®Google Scholar
• Elizondo CR, Bright JD, Byrne JA, Bright RK. Analysis of the CD8+ IL-10+ T cell response elicited by vaccination with the oncogenic tumor-self protein D52. Hum Vaccin Immunother. 2020;16(6):1413–23. doi:10.1080/21645515.2019.1689746.
   PubMed Web of Science ®Google Scholar
• Elizondo CR, Bright JD, Bright RK. Vaccination with a shared oncogenic tumor-self antigen elicits a population of CD8+ T cells with a regulatory phenotype. Hum Vaccin Immunother. 2022;18(6):e2108656-1–14. doi:10.1080/21645515.2022.2108656.
   Web of Science ®Google Scholar
• Bismar TA, Demichelis F, Riva A, Kim R, Varambally S, He L, Kutok J, Aster JC, Tang J, Kuefer R, et al. Defining aggressive prostate cancer using a 12-gene model. Neoplasia. 2006;8(1):59–68. doi:10.1593/neo.05664.
   PubMed Web of Science ®Google Scholar
• Mirshahidi S, Kramer VG, Whitney JB, Essono S, Lee S, Dranoff G, Anderson KS, Ruprecht RM. Overlapping synthetic peptides encoding TPD52 as breast cancer vaccine in mice: prolonged survival. Vaccine. 2009 Mar 13;27(12):1825–33. doi:10.1016/j.vaccine.2009.01.089.
   PubMed Web of Science ®Google Scholar